(R)-BPO-27

(R)-BPO-27, the R enantiomer of BPO-27, is a potent, orally active and ATP-competitive CFTR inhibitor with an IC 50 of 4 nM. In Vitro (R)-BPO-27 exhibits a dose-response inhibition and inhibits the CFTR current by 50% at 0.53 nM in HEK-293T cells. (R)-BPO-27 acts from the cytoplasmic side and has low membrane permeability. (R)-BPO-27 reduces the channel open probability (NPo) from 0.29 to 0.08, modestly reduces in mean channel open time, and strongly increases mean channel closed time in HEK-293T cells expressing human wild-type CFT in a single-channel patch-clamp experiment. Meanwhile, (S)-BPO-27 does not affect any of these parameters. (R)-BPO-27 is applied directly to the cytoplasmic membrane surface and stabilizes the CFTR channel closed state with an IC 50 of 600 pM in Single-channel electrophysiology assay. (R)-BPO-27 (10 μM, 10 min pretreatment) inhibits Cl - current with apparent IC 50 values of 5 and 10 nM for CPT-cAMP and 8-Br-cGMP, respectively, in CFTR-expressing FRT cells after CFTR stimulation by cAMP agonist. the IC 50 of 4 nM for inhibition of forskolin-stimulated CFTR Cl - current in FRT cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo (R)-BPO-27 (interperitoneal administration; 10 mg/kg) decays with t 1/2 ≈1.6 h and gives sustained therapeutic concentrations in kidney in a PK study . (R)-BPO-27 (intraperitoneal injection; 5 mg/kg; 30 min before abdominal surgery) prevents fluid accumulation in closed midjejunal loops produced by cholera toxin, giving an intestinal loop weight/length ratio similar to that in PBS-injected loops. This effect is dose-dependently and the IC 50 value is 0.1 mg/kg. (R)-BPO-27 (intraperitoneal injection or oral administration; 5 mg/kg) shows a slow (R)-BPO-27 metabolism and produces sustained serum (R)-BPO-27 levels for at least 4 h. The AUC analysis gave an oral bioavailability of ∼94% for (R)-BPO-27 in mouse pharmacokinetics and toxicity study. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female CD1 mice (age 8–10 wk)Dosage: 0.05, 0.15, 0.5, 1.5, and 5 mg/kg Administration: Intraperitoneal injection; 5 mg/kg; 30 min before abdominal surgery Result: Exhibited apparent efficacy in mice models of cholera and traveler’s diarrhea. Form:Solid IC50& Target:IC50: 4 nM

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet